详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review

96| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Research Laboratory and Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 434000, Hubei Province, China

出处：

DOI：

ISSN：

关键词： Hepatocellular carcinoma Vascular invasion Surgery Transarterial chemoembolization

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer with a high mortality rate worldwide. The percentage of HCC patients with vascular invasion is high. However, tumor thrombus in the hepatic vein (HVTT) has a lower incidence than tumor thrombus in the portal vein (PVTT). Conventionally, HCC patients with HVTT are treated the same as HCC patients with PVTT and offered sorafenib or other systemic agents. However, according to recent studies, it is evident that HCC with HVTT shows different outcomes when classified into different subgroups. In this review, we discuss the recent progress and changes in treatment of HCC with HVTT.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 3 区医学

小类 | 3 区外科 4 区胃肠肝病学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区胃肠肝病学 4 区外科

JCR分区：

出版当年[2019]版：

Q3 SURGERY Q4 GASTROENTEROLOGY & HEPATOLOGY

最新[2023]版：

Q2 SURGERY Q3 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 1.8 最新[2023版] 1.9 最新五年平均 1.863 出版当年[2019版] 0 出版当年五年平均 0 出版前一年[2018版] 2.582 出版后一年[2020版]

第一作者：

第一作者单位： [1]Research Laboratory and Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 434000, Hubei Province, China

通讯作者：

通讯机构： [1]Research Laboratory and Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 434000, Hubei Province, China [*1]Research Laboratory and Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Road, Wuhan 434000, Hubei Province, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Integrative Functional Genomics Implicated the Key T-/B-Cell Deficiency Regulator RAG1 in Transarterial Chemoembolization of Hepatocellular Carcinoma [2]Novel Prognostic Nomogram to Predict Progression-Free Survival of Patients with Hepatocellular Carcinoma After Transarterial Chemoembolization [3]Adjuvant Transarterial Chemoembolization Plus Immunotherapy for Huge Hepatocellular Carcinoma: A Propensity Score Matching Cohort Study [4]Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients [5]Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study [6]Diabetes mellitus and the neutrophil to lymphocyte ratio predict overall survival in non-viral hepatocellular carcinoma treated with transarterial chemoembolization [7]Comment on "Sub-classification of Microscopic Vascular Invasion in Hepatocellular Carcinoma'' [8]Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review [9]Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study [10]Letter to the editor: Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study